Evidence map›Paper›PMID 26933815›Full record

ArticleOncotarget2016

The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma.

Xiaobo He, Ting Zhou, Guangwei Yang, Wenfeng Fang, Zelei Li, Jianhua Zhan, Yuanyuan Zhao, Zhibin Cheng, Yan Huang, Hongyun Zhao and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Junction Plakoglobin - A Dual-Role Player in Cancer Biology.International journal of surgery (London, England) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiaobo HeDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Ting ZhouDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Guangwei YangDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Wenfeng FangDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Zelei LiDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Jianhua ZhanDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Yuanyuan ZhaoDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Zhibin ChengDepartment of Oncological Radiotherapy, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.
Yan HuangDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Hongyun ZhaoDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Li ZhangDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Sun Yat-sen University · CNSun Yat-sen University Cancer Center · CNState Key Laboratory of Oncology in South China

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to explore the relationship between plakoglobin expression and clinical data in the patients with surgically resected lung adenocarcinoma.

resultsWith follow-up of median 50.14 months, the average PFS and OS were 16.82 and 57.92 months, respectively. In 147 patients, recurrence or death was observed in 131 patients. According to the log-rank test, low plakoglobin expression was a significant predictor for favorable DFS (P=0.006) and OS (P=0.043). For the analyses within subgroups, high plakoglobin expression was an independent factor for reducing DFS in non-metastatic patients with resected lung adenocarcinoma (P < 0.05). Moreover, high plakoglobin expression was associated with poor DFS even receiving adjuvant chemotherapy (P =0.028) and with a shorter DFS (HR, 2.01, 95%CIs, 1.35 to 2.97, P=0.001) and OS (HR, 1.94, 95%CIs, 1.12 to 3.37, P=0.019). PATIENTS AND

methodsThe expression of plakoglobin in 147 primary tumor tissues was examined by using immunohistochemistry and clinical data were collected. The optimal cutoff value of immunoreactivity score (IRS) was calculated and used to divide all the patients into two groups: low-level group (IRS: 0-3, n=59) and high-level group (IRS: 4-12, n=88). Kaplan-Meier curves were applied to assess the plakoglobin expression and clinical variables. The univariate and multivariate Cox model analyses were performed to evaluate the effects of clinical factors and plakoglobin expression on disease-free survival (DFS) and overall survival (OS).

conclusionsHigh plakoglobin expression is an independent negative prognostic factor for patients with surgically resected lung adenocarcinoma.

Indexed as

AdenocarcinomaBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleFollow-Up Studiesgamma CateninHumansLung NeoplasmsMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateBiomarkers, Tumorgamma CateninJUP protein, humanadenocarcinomabiomarkerimmunohistochemistryplakoglobinprognosis in surgically resected lung adenocarcinoma

Identifiers

PMID26933815
PMCPMC4924786
OpenAlexW2311934128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.